Regeneron Pharmaceuticals, Inc. (BMV:REGN)

Market Cap	1.34T
Revenue (ttm)	261.34B
Net Income (ttm)	83.97B
Shares Out	n/a
EPS (ttm)	762.93
PE Ratio	15.97
Forward PE	15.64
Dividend	67.63 (0.49%)
Ex-Dividend Date	Nov 20, 2025

Volume	2,362
Average Volume	317
Open	13,970
Previous Close	n/a
Day's Range	13,789 - 13,989
52-Week Range	9,420 - 15,933
Beta	n/a
RSI	70.26
Earnings Date	Feb 3, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: REGN

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD